@article{64673067bbae4cc4aaa2853a3f75cc5f,
title = "Adjuvant therapy in stage IIIA melanoma - Authors' reply",
author = "Eggermont, {Alexander M.M.} and Stefan Suciu and Caroline Robert",
note = "Funding Information: AMME reports being the study chair of the EORTC 18071/CA-029 phase 3 clinical trial (Bristol Myers Squibb [BMS]) and of the EORTC 1325/KEYNOTE-054 phase 3 trial (Merck Sharp & Dohme), and has worked in a consulting or advisory role and received honoraria from Biocad, Biotech, BioInvent, BMS, CatalYm, GlaxoSmithKline, IO Biotech, ISA Pharmaceuticals, Merck, Novartis, Regeneron Pharmaceuticals, Sellas, and SkylineDx. SS reports receiving grants from Merck. CR has worked in a consulting or advisory role and received honoraria from Amgen, Biothera, BMS, Merck, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Ultimovacs.",
year = "2021",
month = jul,
doi = "10.1016/S1470-2045(21)00354-5",
language = "English",
volume = "22",
pages = "e300",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd.",
number = "7",
}